Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Very long response with trastuzumab for metastatic Her2-positive breast cancer
F. Lai-Tiong1, *
1 Oncology Unit Gard Cancer Institute, NÎmes, France
Eur. J. Gynaecol. Oncol. 2018, 39(6), 1002–1003; https://doi.org/10.12892/ejgo4040.2018
Published: 10 December 2018
Metastatic Her2-positive breast cancer are very aggressive tumors. With the development of anti-Her2 therapies, the prognosis of such tumors has changed. The author reports the case of a 60-year-old woman, diagnosed with a left Her2-positive breast cancer, revealed by a pathological fracture of the right femur (pT1cN1aM1, Stage IV). She received hormonal treatment in association with trastuzumab. She always is under trastuzumab therapy for four years. Anti-Her2 therapies are effective even in metastatic cancer patients.